medmen

At current pace of operation & CAPEX spending, Aurora and Curaleaf have less than two quarters of runway left while iAnthus defaults on debt payment and MedMen needs $250M to execute turnaround plan. [more]

A big merger terminated, an IPO delayed and the first cannabis ETF down almost 60% in share price this past year, has the bloom fallen off the cannabis flower? [more]